Drugs & Targets Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC March 08, 2024Vol.50 No.10
Drugs & Targets FDA, industry actions end sales of PFAS in U.S. food packaging March 01, 2024Vol.50 No.09
Drugs & Targets FDA grants Epkinly priority review sBLA for difficult-to-treat R/R follicular lymphoma March 01, 2024Vol.50 No.09
Drugs & Targets FDA accepts BLA for Tevimbra for 1L treatment of G/GEJ cancers March 01, 2024Vol.50 No.09
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
In Brief House Energy and Commerce Committee Democratic leaders urge FDA to advance clinical trial diversity efforts February 23, 2024Vol.50 No.08
Drugs & Targets Linvoseltamab BLA accepted for Priority Review for R/R multiple myeloma February 23, 2024Vol.50 No.08
